Online Program Home
  My Program

All Times EDT

Abstract Details

Activity Number: 409 - Estimands in Oncology: Papers from an Industry Working Group
Type: Topic-Contributed
Date/Time: Thursday, August 12, 2021 : 2:00 PM to 3:50 PM
Sponsor: Biopharmaceutical Section
Abstract #317320
Title: Utilizing Surrogate Endpoints in Adaptive Designs with Delayed Treatment Effect
Author(s): Jianchang Lin* and Qing Li and Mengya Liu and Liwen Wu
Companies: Takeda Pharmaceuticals and Takeda Pharmaceuticals and Takeda Pharmaceuticals and University of Pittsburgh
Keywords: Adaptive Design; Sample Size Re-Estimation; Surrogate Endpoint; Delayed Treatment Effect; Conditional Power; Oncology

Delayed treatment effects have been commonly observed in clinical trials, which bring more challenges to the interim decision making particularly in adaptive designs setting. An improper interim analysis may falsely stop a promising study based on the traditional conditional power (CP) approach. For such scenario, a short-term surrogate endpoint which is predictive of the primary long-term outcome can be extremely useful for a more accurate CP calculation and adaptative decision. In this paper, we propose utilizing a surrogate endpoint in the interim analysis to improve the CP calculation in designing an adaptive sample size re-estimation (SSR) study. Through theoretic derivation and extensive simulations, we show that our proposed approach demonstrates the practical feasibility and benefits of using a surrogate endpoint for adaptive designs with delayed treatment effects. We also demonstrate proposed approach in case studies of phase III Non-small cell lung cancer (NSCLC) trial with delayed treatment effect as well as Norovirus (NoV) vaccine trial. Finally, we give recommendations on how this method could be implemented in confirmatory clinical trials.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2021 program